Clinical Trials on BRAF V600E Mutation Positive in Belgium
Total 7 results
-
PfizerCompletedSolid Tumors Harboring a BRAF V600 MutationUnited States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
-
Pierre Fabre MedicamentClinactCompletedMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance, United Kingdom, Spain, Belgium, Germany, Italy, Austria
-
Day One Biopharmaceuticals, Inc.RecruitingMelanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditionsUnited States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
-
Pierre Fabre MedicamentPfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdCompletedBRAF V600E-mutant Metastatic Colorectal CancerFrance, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
-
PfizerMerck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre MedicamentCompletedBRAF V600E-mutant Metastatic Colorectal CancerUnited States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
-
Novartis PharmaceuticalsActive, not recruitingBRAF V600 Colorectal CancerBelgium, Germany, Netherlands, Spain, Singapore, Australia, United Kingdom, Israel, Canada, United States
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more